More than 25 million Americans are living with asthma, and, for many, their symptoms can be managed with some combination of inhaled treatment options. For about 5-10% of people with asthma, however, their condition is considered severe, to the point where it remains uncontrolled despite treatment.1 People with uncontrolled asthma often find themselves juggling multiple therapies to avoid debilitating asthma attacks, emergency department visits or hospitalization.2,3
“I live with a very real fear that everyday activities like a walk in the park or petting my neighbor’s dog could land me in the emergency room,” said one patient, who is living with severe asthma. “Everything I do is done through the lens of ‘Can my lungs handle it?', which is a tough way to live.”
The underlying role of type 2 inflammation
Type 2 (T2 inflammation) can be an underlying driver of severe asthma.4 Research shows this inflammation is the underlying pathology for more than 80% of people with the condition.5 IL-5 is a key signaling protein (cytokine) in T2 Inflammation.4 GSK has pioneered research into long-term dosing treatments that target IL-5 in people living with severe asthma, to address this underlying driver with the goal of providing long-term management of these diseases.
“IL-5 targeting agents have transformed the way we manage the treatment of severe respiratory diseases, Through continued exploration of eosinophilic, mucosal inflammation and the understanding of the key role in IL-5, we now have the potential to safely and effectively reduce exacerbations over an extended period of time, lowering the treatment burden while offering sustained disease management for patients.”
Long-term dosing is on the horizon
Adherence with prescribed treatments is critically important for individuals to manage respiratory diseases, and poor adherence is associated with worsening symptoms and increased risk of exacerbations.6 Experts are continuing to explore therapies with longer dose intervals as an option to address real world problems when it comes to biologic therapy, improving the treatment experience and optimizing medication adherence.
We have recently begun to understand the impact of treatment adherence and its challenges to the effective management of chronic respiratory conditions, leaving millions of people at the mercy of their disease, we believe that patients deserve more options for severe asthma, and we’re exploring therapeutic options that offer the potential for less frequent dosing.”
References
1. American Lung Association. Severe Asthma. Available at: https://www.lung.org/lung-health-diseases/lung-disease-lookup/asthma/learn-about-asthma/types/severe-asthma.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Updated May 2024. Available at: https://ginasthma.org/. Last accessed November 2025.
3. World Health Organization. Asthma Key Facts. Available at: https://www.who.int/news-room/fact-sheets/detail/asthma. Last accessed November 2025.
4. “What Is Type 2 Inflammation?” Allergy & Asthma Network, 22 May 2025, https://allergyasthmanetwork.org/health-a-z/type-2-inflammation-resources/
5. Heaney LG, et al. Eosinophilic and noneosinophilic asthma. CHEST. 2021;160:814–30. DOI: 10.1016/j.chest.2021.04.013
6. Kwiatek J, Alfonso-Cristancho R, Wang J, et al. Low adherence to current biologic therapies in asthma: Insights from a retrospective cohort analysis of claims data. J Allergy Clin Immunol. 2025;155(2 Suppl):AB439. DOI: 10.1016/j.jaci.2024.12.1009.
